Detection of Adalimumab and Anti-Adalimumab Levels by ELISA: Clinical Considerations

Drug Development Research

Volumn 75, Issue , 2014, Pages S11-S14

  Marinari, Barbara ^a   Botti, Elisabetta ^a   Bavetta, Mauro ^b   Spallone, Giulia ^b   Zangrilli, Arianna ^b   Talamonti, Marina ^b   Richetta, Antonio ^c   Chimenti, Sergio ^b   Costanzo, Antonio ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

adalimumab; anti adalimumab antibody; assay; promonitor assay; serum concentrations

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; DRUG ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY DETECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; IMMUNOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84910025712     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21186     Document Type: Review

References (6)

1. Aggarwal BB, Gupta SC, Kim JH,. 2012. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119: 651-665.
2. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ,. 2011. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 14: 1460-1468.
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ,. 2007. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 7: 921-926.
4. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, et al. 2009. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 5: 1628-1640.
5. Reich K,. 2012. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 26 (Suppl. 2): 3-11.
6. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B,. 2006. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 3: 711-715.